We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFLX.L Regulatory News (FLX)

  • There is currently no data for FLX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Falanx Launch Mass Market Security Assessment Tool

4 Oct 2021 07:00

RNS Number : 8274N
Falanx Group Limited
04 October 2021
 

04 October 2021

FALANX GROUP LIMITED

("Falanx", the "Group" or the "Company")

Falanx Cyber Launches Mass Market Cyber Security Assessment Tool

Falanx Group Limited (FLX.L), the AIM listed provider of cyber security and strategic intelligence services, is pleased to announce the launch of its new cyber security assessment tool, Falanx: Cyber Exposure Level ("f:CEL").

 

This new service offering is expected to play an important role in Falanx's reconnaissance stage of performing a cyber security risk assessment on businesses in order to assess their overall risk of being attacked or breached. f:CEL uses a multi-point reconnaissance approach to allow an external, non-invasive, light touch approach which requires minimal input from the user. The findings of this new assessment tool are displayed as a Falanx Cyber Exposure Level score. The f:CEL score is comprised of three elements:

 

· Digital Risk - assesses a company's Web and Dark Web content, including its website security

 

· External IP Risk - assesses the security level of a company's public-facing servers

 

· Organisational Risk - assesses how effective a company's operations are in minimising their risk of attack

 

The user submits an easy-to-complete, quick, multiple-choice, online questionnaire following which f:CEL runs its analytical and diagnostic tools before providing its findings and recommendations the next working day. Following the initial sign-up report, f:CEL update checks can be performed regularly so that a business can keep track of their security posture. Each report run provides incremental remedial recommendations for the business to action as well as visibility on how their security posture improves over time.

 

f:CEL is sold on a subscription basis and is consequently expected to generate high quality recurring revenues. Various large channel partners have already expressed their interest in deploying this into their customer bases. Consequently, the Board believes that there is potential for growth, not only from sales of f:CEL itself, but also through incremental follow-on sales of cyber security services such as monitoring and penetration testing.

 

Mike Read, CEO, commented: 

 

"Falanx Cyber has developed a mass-market, technology that will perform an objective and repeatable cyber security risk assessment on businesses. We believe this is an ongoing requirement for companies, of all sizes, in order to maintain a robust resilience against cyber threats"

 

"f:CEL is affordable and easily accessible for all sizes of business and can be deployed via larger partners. Initial deployments have already generated valuable insights to organisations, as well as discussions of sales of other Falanx services. f:CEL will allow executives to plan and budget to address weak areas and, perhaps more significantly, provide Board members with evidence on how they are looking after the business on behalf of all their stakeholders."

 

For more information, please visit https://falanxcyber.com/fcel/

 

 

 

Enquiries:

 

Falanx Group Limited

Alex Hambro Chairman

Mike Read CEO

Ian Selby CFO

 

Via IFC

Stifel Nicolaus Europe Limited, Nomad and Joint Broker

Alex Price / Fred Walsh

+ 44 (0) 207 710 7600

 

IFC Advisory Ltd, Financial PR & IR

Graham Herring / Zach Cohen

 

+44 (0) 203 934 663

 

 

About Falanx

Falanx Group Limited, is a global intelligence and cyber defence provider working with blue chip and government clients. For more information: https://www.falanx.com/

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMJBLTMTBMBRB
Date   Source Headline
9th Dec 20222:42 pmRNSHolding(s) in Company
8th Dec 20224:29 pmRNSResult of AGM
8th Dec 20227:00 amRNSInterim Results
24th Nov 20225:17 pmRNSHolding(s) in Company
15th Nov 20225:56 pmRNSNotice of AGM
18th Oct 20227:00 amRNSDirectorate Change
29th Sep 20227:00 amRNSFinal Results
20th Sep 20227:00 amRNSHolding(s) in Company
5th Sep 20224:53 pmRNSHolding(s) in Company
4th Aug 20222:06 pmRNSSecond Price Monitoring Extn
4th Aug 20222:00 pmRNSPrice Monitoring Extension
4th Aug 202211:05 amRNSSecond Price Monitoring Extn
4th Aug 202211:00 amRNSPrice Monitoring Extension
4th Aug 20227:00 amRNSTrading Update
9th May 20227:00 amRNSPartnership to Provide M-EDR to UK Customers
8th Apr 20224:06 pmRNSHolding(s) in Company
6th Apr 202211:59 amRNSHolding(s) in Company
1st Apr 20227:00 amRNSChange of Adviser
30th Mar 20222:44 pmRNSDirector/PDMR Shareholding
23rd Mar 202212:59 pmRNSDirector/PDMR Shareholding
10th Feb 202211:11 amRNSDirector/PDMR Shareholding
24th Jan 20227:00 amRNSDirector/PDMR Shareholding
19th Jan 20225:20 pmRNSHolding(s) in Company
19th Jan 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 202111:14 amRNSResult of AGM
7th Dec 20217:00 amRNSInterim Results
16th Nov 20212:10 pmRNSNotice of AGM
29th Oct 20211:57 pmRNSExercise of Options, TVR and PDMR dealing
27th Oct 20219:03 amRNSDirector/PDMR Shareholding
26th Oct 20217:00 amRNSDirector/PDMR Shareholding
25th Oct 20213:25 pmRNSExercise of Options and TVR
13th Oct 202111:06 amRNSSecond Price Monitoring Extn
13th Oct 202111:00 amRNSPrice Monitoring Extension
13th Oct 20217:00 amRNSTrading update and BOOST&Co loan facility update
6th Oct 20214:41 pmRNSSecond Price Monitoring Extn
6th Oct 20214:35 pmRNSPrice Monitoring Extension
6th Oct 20212:43 pmRNSSale of Assynt for £4.6 million
4th Oct 20217:00 amRNSFalanx Launch Mass Market Security Assessment Tool
29th Sep 20217:00 amRNSAnnual results for the year ended 31 March 2021
18th Aug 20217:01 amRNSGrant of share options
18th Aug 20217:00 amRNSTrading Update & New Loan Facility
9th Jul 20219:07 amRNSHolding(s) in Company
29th Apr 20217:00 amRNSCancellation of unapproved Share Options
1st Apr 20217:00 amRNSIssue of Equity and TVR
26th Feb 20213:31 pmRNSResult of GM
10th Feb 20212:03 pmRNSPublication of Circular & Notice of GM
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
5th Feb 20217:00 amRNSContract Wins and Covid Business Interruption Loan
18th Jan 20212:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.